Recursion Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912" ], "revenue_estimate": [ 65.27, 85.33, 153.71, 247.5 ], "ebit_estimate": [ -507.78, -495.81, -449.98, -593.5 ], "ebitda_estimate": [ -452.49, -447.21, -380.46, null ], "net_income_estimate": [ -487.89, -484.9, -403.18, -546.5 ], "per_share_eps_estimate": [ -0.93, -0.91, -1.08, -0.94 ], "eps_nri_estimate": [ -0.92, -0.9, -0.72, -0.94 ], "dividend_estimate": [ null, null, null, null ], "book_value_per_share_estimate": [ 1.34, 0.69, 0.83, null ], "pretax_income_estimate": [ -487.89, -494.86, -403.18, -548.5 ], "operating_cash_flow_per_share_estimate": [ -0.39, -0.56, null, null ], "roa_estimate": [ -46.2, -57, null, null ], "roe_estimate": [ -56.71, -110.12, -85.08, null ], "gross_margin_estimate": [ 100, 23.8, 50, 55 ], "operating_cash_flow_estimate": [ -203.78, -293.76, null, null ], "pettm_estimate": [ 0, 0, 0, 0 ], "long_term_growth_rate_mean": 18.98, "long_term_revenue_growth_rate_mean": "27.55", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 18.98, "future_revenue_estimate_growth": 27.55, "future_ebit_estimate_growth": 10.58, "future_ebitda_estimate_growth": 11.26, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 13.19, "future_pretax_income_estimate_growth": 13.02, "future_book_value_per_share_estimate_growth": -29.55, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -18.94, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 12.23, 18.63, 26.85, 13.23, 18.4, 18.53, 36.13, 5.2 ], "ebit_estimate": [ -126.12, -127.26, -133.74, -121.32, -115.85, -115, -136.15, null ], "ebitda_estimate": [ -113.88, -115.71, -128.48, -132.38, null, null, null, null ], "net_income_estimate": [ -119.38, -122.08, -128.56, -121, -121, -123, -123, null ], "per_share_eps_estimate": [ -0.22, -0.23, -0.22, -0.23, -0.23, -0.23, -0.23, null ], "eps_nri_estimate": [ -0.23, -0.23, -0.22, -0.23, -0.24, -0.23, -0.2, null ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -122.4, -100.9, -101.4, null, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 25, 25, 25.5, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 18.98, "long_term_revenue_growth_rate_mean": "27.55", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 18.98, "future_revenue_estimate_growth": 27.55, "future_ebit_estimate_growth": 10.58, "future_ebitda_estimate_growth": 11.26, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 13.19, "future_pretax_income_estimate_growth": 13.02, "future_book_value_per_share_estimate_growth": -29.55, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -18.94, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }